- Exchange: OTC US
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Progen Pharmaceuticals Ltd
+ Add to WatchlistPGLA:US
0.2000 USD 0.00000.00%As of 20:10:00 ET on 05/17/2013.
Snapshot for Progen Pharmaceuticals Ltd (PGLA)
| Open: | - | Day's Range: | - | Volume: | 500 |
|---|---|---|---|---|---|
| Previous Close: | 0.2000 | 52wk Range: | 0.1085 - 0.2621 | 1-Yr Rtn: | +10.64% |
Key Statistics for PGLA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 2,039 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 09/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for PGLA
Company Profile & Key Executives for PGLA
Progen Pharmaceuticals Limited is involved in the discovery, research and development of potential biopharmaceutical therapeutics for the treatment of human diseases. The Company also provides contract services related to the process development, manufacture and quality assurance of biological products.
| Fleur LankesheerDir:Bus Development & Legal | Michael FitzgeraldDir:Clinical Operations |
| Darryn BamptonDir:Clinical & Regulatory | Blair LucasSecretary |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
PGLA News
-
Industry News
No stories found
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page